VX-765 is an inhibitor of NLRP3 inflammasome activity; it inhibits caspase 1 and IL-1β cleavage and release. VX-765 exhibits anti-inflammatory, antidepressant, and antiepileptic activities. In vivo, this compound decreases IL-1β levels and attenuates stress-induced depression-like behaviors. In animal models of status epilepticus, VX-765 decreases cell loss. In other similar animal models, this compound decreases chronic epileptic activity and delays onset of acute seizures.
| Cas No. | 273404-37-8 |
|---|---|
| Purity | ≥98% |
| Formula | C24H33ClN4O6 |
| Formula Wt. | 509.00 |
| IUPAC Name | N-(4-Amino-3-chlorobenzoyl)-3-methylvalyl-N-[(2R,3S)-2-ethoxy-5-oxotetrahydro-3-furanyl]-L-prolinamide |
| Synonym | VX765,Belnacasan |
| Solubility | DMSO 100 mg/mL warmed (196.46 mM) Ethanol 100 mg/mL warmed (196.46 mM) Water Insoluble |
| Appearance | Light yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zhang Y, Liu L, Liu YZ, et al. NLRP3 Inflammasome Mediates Chronic Mild Stress-induced Depression in Mice via Neuroinflammation. Int J Neuropsychopharmacol. 2015 Jan 20. [Epub ahead of print]. PMID: 25603858.
Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics. 2014 Apr;11(2):385-400. PMID: 24671870.
Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013 Nov;59:183-93. PMID: 23938763.
Maroso M, Balosso S, Ravizza T, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011 Apr;8(2):304-15. PMID: 21431948.
